ArticleCase reports in oncology
Alectinib-Induced Erythema Multiforme and Successful Rechallenge with Alectinib in a Patient with Anaplastic Lymphoma Kinase-Rearranged Lung Cancer.
Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 13 citations in OpenAlex.
- Real-world safety profile of alectinib: a 10-year pharmacovigilance study based on the FDA adverse event reporting system.Frontiers in medicine · 2026Article
- Erythema multiforme-like targetoid eruption in two patients treated with capivasertib for metastatic breast cancer.JAAD case reports · 2024Article
- Alectinib-induced rash unresponsive to desensitization: a case report and literature review.BMC pulmonary medicine · 2023Review
- Severe Skin Toxicity Caused by Sequential Anti-PD-1 Antibody and Alectinib in Non-small-cell Lung Cancer: A Report of Two Cases and a Literature Review.Internal medicine (Tokyo, Japan) · 2022Review
- Alectinib-associated drug reaction with eosinophilia and systemic symptoms syndrome.JAAD case reports · 2020Article
- Patients with high-grade alectinib-induced skin rash: How do we desensitize these patients? A case report and review of literature.SAGE open medical case reports · 2020Article
- Current Perspectives on Erythema Multiforme.Clinical reviews in allergy & immunology · 2018Review
- Hypersensitivity in ALK-positive lung cancers exposed to ALK inhibitors: a case of successful switch to an alternative ALK inhibitor and systematic review of the literature.Lung Cancer (Auckland, N.Z.) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlectinib is an oral drug developed for the treatment of patients with fusion gene encoding echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase ( CASE PRESENTATION: A 39-year-old woman who was a passive smoker was referred to Osaka City University Hospital for the evaluation of a skin event caused by treatment for NSCLC with the fusion gene
conclusionTo the best of our knowledge, we present the first case in which alectinib, which binds to the adenosine triphosphate site of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.